Establishment Labs (NASDAQ:ESTA) Price Target Cut to $74.00 by Analysts at Citigroup

Establishment Labs (NASDAQ:ESTA) had its price objective reduced by research analysts at Citigroup from $81.00 to $74.00 in a research report issued on Wednesday,Benzinga reports. The brokerage currently has a “neutral” rating on the stock. Citigroup’s price objective points to a potential upside of 12.14% from the stock’s previous close.

Several other analysts also recently issued reports on ESTA. Stephens boosted their price objective on Establishment Labs from $85.00 to $90.00 and gave the stock an “overweight” rating in a report on Wednesday, February 25th. JPMorgan Chase & Co. lifted their target price on shares of Establishment Labs from $71.00 to $80.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 17th. Weiss Ratings restated a “sell (e+)” rating on shares of Establishment Labs in a report on Monday, December 29th. Canaccord Genuity Group upped their price target on shares of Establishment Labs from $85.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. Finally, Wall Street Zen upgraded shares of Establishment Labs from a “hold” rating to a “buy” rating in a research report on Saturday. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $86.86.

Establishment Labs Price Performance

Shares of NASDAQ ESTA traded down $0.36 during mid-day trading on Wednesday, reaching $65.99. 137,408 shares of the company traded hands, compared to its average volume of 517,331. Establishment Labs has a fifty-two week low of $26.56 and a fifty-two week high of $83.31. The firm has a market cap of $1.93 billion, a PE ratio of -37.95 and a beta of 0.91. The stock has a fifty day simple moving average of $70.68 and a 200-day simple moving average of $60.19. The company has a debt-to-equity ratio of 10.51, a current ratio of 3.04 and a quick ratio of 2.00.

Establishment Labs (NASDAQ:ESTA) last issued its quarterly earnings results on Tuesday, February 24th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.13. Establishment Labs had a negative return on equity of 201.79% and a negative net margin of 24.19%.The firm had revenue of $64.62 million during the quarter, compared to analyst estimates of $63.80 million. During the same period last year, the company posted ($1.19) EPS. The firm’s quarterly revenue was up 45.2% on a year-over-year basis. Equities research analysts anticipate that Establishment Labs will post -2.41 EPS for the current fiscal year.

Institutional Trading of Establishment Labs

Several large investors have recently modified their holdings of the company. Kestra Advisory Services LLC acquired a new position in Establishment Labs in the 4th quarter valued at $47,000. Quarry LP acquired a new stake in shares of Establishment Labs in the third quarter valued at about $34,000. State of Wyoming bought a new position in shares of Establishment Labs in the third quarter worth about $71,000. MV Capital Management Inc. acquired a new position in shares of Establishment Labs during the 4th quarter worth about $146,000. Finally, Osaic Holdings Inc. lifted its position in shares of Establishment Labs by 900.0% during the 2nd quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock worth $85,000 after purchasing an additional 1,800 shares during the last quarter. 72.91% of the stock is owned by institutional investors.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.